New drug combo aims to boost chemo for rare blood cancer
NCT ID NCT07676175
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether adding the experimental drug BEBT-908 to standard CHOP chemotherapy works better than CHOP alone for people with previously untreated peripheral T-cell lymphoma (PTCL). The trial first explores different dosing schedules to find the best way to combine the drugs, then compares the optimal combination against standard CHOP. About 120 adults aged 18 to 75 with PTCL will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BEBT-908 (ifupinostat hydrochloride) plus CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for peripheral T-cell lymphoma, potentially improving response rates and delaying disease progression.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The combination may cause more side effects than standard chemo, and it is not yet known if it will lead to better long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, 710061, China